← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Boston Immune Technologies And Therapeutics, Inc.
Winchester, MA
$7,596,287
Total funding
2
Grants
Funding over time
peak $3.3M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,596,287 · 2
By mechanism
R44$7,596,287 · 2
Investigators at Boston Immune Technologies And Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).$2,409,283
R44 · FY2025 · CA
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).$1,565,481
R44 · FY2024 · CA
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy$1,221,684
R44 · FY2023 · CA
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.$926,858
R44 · FY2025 · AI
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy$776,973
R44 · FY2024 · CA
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy$397,959
R44 · FY2021 · CA
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.$298,049
R44 · FY2023 · AI